Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Nations stockpile mpox vaccine amid rising geopolitical fears
9 Jul 2025, 14:48BAVA.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 23 April 201523 Apr 2015
Total number of voting rights and share capital in Bavarian Nordic A/S31 Mar 2015
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting27 Mar 2015
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants24 Mar 2015
Bavarian Nordic A/S - Articles of Association24 Mar 2015
Bavarian Nordic A/S - Major Shareholder Announcement13 Mar 2015
Bavarian Nordic Announces 2014 Full Year Results11 Mar 2015
Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy
Search

Danish vaccine maker Bavarian Nordic will supply an undisclosed European country with its smallpox and mpox vaccine under a new contract valued at over 200 million Danish Krone, the company announced Wednesday.

Bavarian Nordic sells vaccine voucher for $160 million
20 Jun 2025, 17:26BAVA.CONASDAQ Copenhagen

Danish vaccine company Bavarian Nordic has entered an agreement to sell a Priority Review Voucher for a total of $160 million, the company said Wednesday.

  • Previous
  • 1
  • 2
  • 3
  • Next
4 Mar 2015
Bavarian Nordic Announces Updated Overall Survival Data from Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the 2015 Genitourinary Cancers Symposium24 Feb 2015
Bavarian Nordic A/S - Major Shareholder Announcement27 Jan 2015
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN® Filo and Janssen's AdVac® technology6 Jan 2015
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC® in Prostate Cancer10 Dec 2014
  • Previous
  • 1
  • More pages
  • 38
  • 39
  • 40
  • More pages
  • 78
  • Next
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
Filings
927